Drug intelligence / Profile preview

ALK-depot SQ 510 Milbenmischung

Development stage: Unknown
Lead developer: ALK Abelló
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

ALK-depot SQ 510 Milbenmischung is a subcutaneous allergen immunotherapy (SCIT) product developed by ALK-Abelló. It consists of a standardized mixture of purified natural allergens from two house dust mite species, *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, in equal proportions. The allergens are adsorbed onto aluminum hydroxide, which acts as an adjuvant to provide a depot effect, allowing for gradual release and prolonged immune stimulation. The product is indicated for the treatment of IgE-mediated house dust mite allergy and has been investigated in Phase 3 clinical trials for the treatment of atopic dermatitis in adults with proven sensitization to house dust mites. The therapy involves a dose-escalation phase followed by a maintenance phase, aiming to induce immunological tolerance and reduce allergic symptoms.

Brand names: ALK-depot SQ 510 MilbenmischungALK-depot SQ
Other names: house dust mite allergen extractDermatophagoides pteronyssinus and Dermatophagoides farinae allergen extractMilbenmischung 510Milbenmischung510Milbenmischung-510ALK-depot SQ house dust mite mixture

Targets

TCR (T cell antigen receptor complex)HDM-specific IgE (House dust mite-specific immunoglobulin E)

Beyond the preview

Go deeper on ALK-depot SQ 510 Milbenmischung.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALK-depot SQ 510 Milbenmischung.

Explore the full profile